Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.59 |
| ▸ | F7 | P08709 | 14/20 | 0.59 |
| ▸ | F3 | P13726 | 14/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.56 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247707 | 0.96 | F2 (0.60) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7449497 | 0.87 | TPSAB1 (0.57) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7020450 | 0.87 | TPSAB1 (0.54) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7021593 | 0.86 | TPSAB1 (0.53) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL3266642 | 0.85 | F2 (0.53) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7403728 | 0.84 | TPSAB1 (0.49) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL3242830 | 0.84 | F2 (0.66) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL5846880 | 0.83 | F7 (0.61) | F2F7F3PRSS1 | |
| SCHEMBL7021053 | 0.83 | TPSAB1 (0.51) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7140320 | 0.83 | F2 (0.47) | F2F7F3PRSS1TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030110-B2 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1303510-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6476016-B2 | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002006248-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | F2 12/4885F7 42/4885F3 22/4885 |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | F2 12/4885F7 42/4885F3 22/4885 |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, TFPI, F12 | F2 9/4885F7 42/4885F3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.